South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

the premier pharmaceutical co ltd - capsule - each capsule contains clofibrate 500 mg

Canada - English - Health Canada

ayerst laboratories - clofibrate - capsule - 500mg - clofibrate 500mg - fribic acid derivatives

Canada - English - Health Canada

novopharm limited - clofibrate - capsule - 500mg - clofibrate 500mg - fribic acid derivatives

Canada - English - Health Canada

wyeth-ayerst canada inc. - clofibrate - capsule - 1g - clofibrate 1g - fribic acid derivatives

Canada - English - Health Canada

wyeth-ayerst canada inc. - clofibrate - capsule - 500mg - clofibrate 500mg - fribic acid derivatives

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - clofibrate 500mg - liquid filled capsule - 500 mg - active: clofibrate 500mg excipient: amaranth gelatin glycerol sodium ethyl hydroxybenzoate sodium propyl hydroxybenzoate

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - clofibrate 500mg - capsule - 500 mg - active: clofibrate 500mg

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - clofibrate 500mg - capsule - 500 mg - active: clofibrate 500mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca - clofibrate - capsule - 500 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clofibrate, quantity: 500 mg - capsule, soft - excipient ingredients: glycerol; sorbitol; sodium propyl hydroxybenzoate; gelatin; sodium ethyl hydroxybenzoate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. updated pregnancy risk category was approved as specified in the letter of 1 july 1992 from dr b. varma. indicated treatment: 1. primary dysbetalipoprotinaemia (type iii hyperlipidaemia) that does not respond adequately to diet; and 2. adult patients with very high serum triglyceride levels (types iv and v hyperlipidaemia) who present a risk of abdominal pain and who do not respond adequately to a determined dietary effort to control them. patients with triglycerides in excess of 750mg per decilitre are likely to present such a risk. indications as at 15 june 1994: col is indicated for primary dysbetalipoproteinaemia (type iii hyperlipidaemia) that does not respond adequately to diet. col may also be considered for the treatment of adult patients with very high serum triglyceride levels (types iv and v hyperlipidaemia) who present a risk of abdominal pain and pancreatitis and who do not respond adequately t